Comparison of azapropazone and naproxen in rheumatoid arthritis.
A double-blind crossover trial was carried out in 15 patients with definite rheumatoid arthritis to compare the effectiveness of 1200 mg azapropazone daily and 750 mg naproxen daily, each drug being given for 2 weeks. Patients also received placebo therapy before and between the two treatment periods. The results of subjective and objective assessments showed that both drugs were significantly superior to placebo, but no significant difference could be demonstrated between the two drugs.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001032:Apazone / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009280:Naphthaleneacetic Acids / Q000627:therapeutic use*; D009288:Naproxen / Q000627:therapeutic use*; D010919:Placebos; D014227:Triazines / Q000627:therapeutic use*
D009280:Naphthaleneacetic Acids; D010919:Placebos; D014227:Triazines; D009288:Naproxen; D001032:Apazone